MATTOSCIO, DOMENICO
 Distribuzione geografica
Continente #
NA - Nord America 937
EU - Europa 660
AS - Asia 237
SA - Sud America 4
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.843
Nazione #
US - Stati Uniti d'America 922
IE - Irlanda 160
IT - Italia 123
SE - Svezia 101
CN - Cina 100
UA - Ucraina 76
TR - Turchia 64
GB - Regno Unito 52
FR - Francia 49
DE - Germania 32
IN - India 29
RU - Federazione Russa 27
SG - Singapore 24
FI - Finlandia 16
CA - Canada 15
BE - Belgio 7
VN - Vietnam 7
IR - Iran 5
NL - Olanda 5
BR - Brasile 4
KR - Corea 4
AU - Australia 3
CZ - Repubblica Ceca 2
ES - Italia 2
EU - Europa 2
IL - Israele 2
JP - Giappone 2
PL - Polonia 2
RO - Romania 2
MT - Malta 1
NO - Norvegia 1
PT - Portogallo 1
RS - Serbia 1
Totale 1.843
Città #
Chandler 239
Dublin 158
Jacksonville 97
Princeton 76
Ashburn 66
Dearborn 55
Southend 44
Izmir 34
Ann Arbor 33
Nanjing 33
Altamura 29
New York 29
Boardman 19
Chieti 18
Houston 17
Beijing 16
Nanchang 15
Rome 14
San Mateo 14
Wilmington 14
Cambridge 13
Montreal 13
Washington 13
Singapore 11
Augusta 7
Brussels 7
Dong Ket 7
Kunming 6
Norwalk 5
Changsha 4
Jiaxing 4
Jundiaí 4
Milan 4
Napoli 4
Prato 4
Rochester 4
Saint-Saens 4
Seattle 4
Tianjin 4
Alba 3
Amsterdam 3
Andover 3
Hebei 3
Shenyang 3
Woodbridge 3
Aprilia 2
Düsseldorf 2
Grevenbroich 2
Helsinki 2
Islington 2
Jinan 2
Lappeenranta 2
Munich 2
Ness Ziona 2
Ningbo 2
Phoenix 2
Redwood City 2
Rouen 2
San Cristóbal de La Laguna 2
Sinalunga 2
Tokyo 2
Toronto 2
Woburn 2
Adelaide 1
Antalya 1
Atlanta 1
Azzano San Paolo 1
Baotou 1
Belgrade 1
Bellante 1
Brno 1
Cachan 1
Carrara 1
Catania 1
Centrale 1
Charlotte 1
Cupertino 1
Denver 1
Edinburgh 1
Giresun 1
Greifswald 1
Haikou 1
Heidelberg 1
Hoffman 1
Hwaseong-si 1
Jinhua 1
Kurrara 1
Lanciano 1
Lanzhou 1
Lisbon 1
Los Angeles 1
Louisville 1
Melita 1
Mountain View 1
Newcastle Upon Tyne 1
Novara 1
Oslo 1
Paris 1
Piotrkow Trybunalski 1
Pittsburgh 1
Totale 1.233
Nome #
Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection 123
Variability in the Recovery Rate of Platelet Cyclooxygenase Activity During Chronic Therapy With Low-Dose Aspirin in Type 2 Diabetes. 100
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: Impact on mediators and mechanisms of the inflammatory response 90
Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity 89
The Recovery of Platelet Cyclooxygenase Activity Explains Interindividual Variability in Responsiveness to Low-Dose Aspirin in Patients With and Without Diabetes. 87
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. 76
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 75
HARNESSING RESOLUTION MEDIATORS AS NOVEL THERAPEUTICS FOR CYSTIC FIBROSIS 74
Resolvin D1 promotes resolution of inflammation, infection, and damage in CF 74
Circulating endothelial progenitor cells and low-dose-aspirin-insensitive thromboxane biosynthesis in polycythemia rubra vera. 72
RESOLVIN D1 FOR TARGETING LUNG INFLAMMATION, INFECTION, AND DAMAGE IN CF 72
Cyanidin reduces preadipocyte differentiation and relative ChREBP expression 71
Resolvin D1 improves airway inflammation and exercise capacity in cystic fibrosis lung disease. 68
ACTIONS OF RESOLVIN D1 AND D2 IN CYSTIC FIBROSIS MRSA LUNG INFECTION AND INFLAMMATION 68
Determinants of the Variability in the Recovery Rate of Platelet Cyclooxygenase Activity during Chronic Therapy with Low-Dose Aspirin in Type 2 Diabetes 66
Proteomics investigation of human platelets in healthy donors and cystic fibrosis patients by shotgun nUPLC-MSE and 2DE: a comparative study 65
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. 64
Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis 63
Resolvin D1 Reduces Lung Infection and Inflammation Activating Resolution in Cystic Fibrosis 55
Resolvin D1 reduces cancer growth stimulating a protective neutrophil-dependent recruitment of anti-tumor monocytes 53
Clinical and laboratory phenotype associated with the aspirin-like defect. 52
PROTECTIVE ROLE OF RVD1 AND ITS RECEPTOR IN CYSTIC FIBROSIS 52
Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages 42
Editorial: HPV and Host Interaction 41
Recent Highlights: Onco Viral Exploitation of the SUMO System 37
Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer 34
Roles of specialized pro-resolving lipid mediators in autophagy and inflammation 29
Autophagy regulates UBC9 levels during viral-mediated tumorigenesis 29
Immunogold Electron Microscopy of the Autophagosome Marker LC3 26
Dynamic phosphorylation of Histone Deacetylase 1 by Aurora kinases during mitosis regulates zebrafish embryos development 26
Specialized pro-resolving lipid mediators and resolution of viral diseases 22
BC-box protein domain-related mechanism for VHL protein degradation 22
Human papilloma virus and autophagy 20
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 19
The SUMO conjugating enzyme UBC9 as a biomarker for cervical HPV infections 16
SUMO pathway components as possible cancer biomarkers 15
In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury 14
SUMO Ubc9 enzyme as a viral target 13
Totale 2.014
Categoria #
all - tutte 8.903
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.903


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020274 75 12 1 1 30 31 51 19 6 17 27 4
2020/2021203 15 7 26 7 11 27 10 5 44 28 10 13
2021/2022218 5 10 1 41 9 1 9 12 12 27 11 80
2022/2023602 47 94 36 55 53 109 29 52 81 13 19 14
2023/2024386 21 18 23 20 31 112 49 30 6 25 16 35
2024/202540 40 0 0 0 0 0 0 0 0 0 0 0
Totale 2.014